STOCK TITAN
  1. Home
  2. Sec-filings
  3. SPRY
  4. [144] ARS Pharmaceuticals, Inc. SEC Filing

ARS Pharmaceuticals (NASDAQ: SPRY) insider lines up new stock sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

ARS Pharmaceuticals, Inc. (SPRY) received a notice under Rule 144 that Sarina Tanimoto, identified on the form as an officer or 10% stockholder, intends to sell company common stock. The notice covers 25,000 shares of common stock, to be acquired from the issuer via a stock option exercise for cash and proposed for sale on or about 08/19/2026 through Morgan Stanley Smith Barney LLC on NASDAQ. The form also reports that Tanimoto sold 49,401 common shares during the prior three months for aggregate proceeds of $311,191.72.

Positive

  • None.

Negative

  • None.
Shares proposed for sale 25,000 shares Common stock covered by the Rule 144 notice
Aggregate market value of proposed sale $161,170.00 Estimated value of 25,000 shares listed in the securities information section
Proposed sale date 08/19/2026 Date associated with the 25,000-share Rule 144 sale and option exercise
Shares sold in past 3 months 49,401 shares Common stock sold by Sarina Tanimoto on 08/18/2026
Aggregate proceeds from past sale $311,191.72 Total consideration for 49,401 shares sold on 08/18/2026
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
10% Stockholder regulatory
"Officer 10% Stockholder"
Stock Option Exercise financial
"Common | 08/19/2026 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
aggregate market value financial
"Common | Morgan Stanley Smith Barney LLC Executive Financial Services ... | 25000 | 161170.00"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does the Form 144 filing for ARS Pharmaceuticals (SPRY) disclose?
It discloses that Sarina Tanimoto, identified as an officer or 10% stockholder, has filed a Rule 144 notice to sell 25,000 shares of ARS Pharmaceuticals common stock following a stock option exercise for cash.

How many ARS Pharmaceuticals (SPRY) shares are covered by the new Rule 144 notice?
The notice covers 25,000 shares of ARS Pharmaceuticals common stock. These shares are expected to be acquired from the issuer on 08/19/2026 via a stock option exercise paid in cash, then may be sold on NASDAQ.

What prior ARS Pharmaceuticals (SPRY) share sales did Sarina Tanimoto report?
The filing reports that Sarina Tanimoto sold 49,401 shares of ARS Pharmaceuticals common stock on 08/18/2026 for aggregate proceeds of $311,191.72 during the past three months, as required disclosure under Rule 144 aggregation rules.

Which broker is listed for the planned ARS Pharmaceuticals (SPRY) Rule 144 sale?
The proposed sale is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, with trading expected on NASDAQ. The form shows an aggregate market value of $161,170.00 for the 25,000 shares covered by this notice.

What is the nature of the ARS Pharmaceuticals (SPRY) shares to be sold under this Form 144?
The 25,000 shares are common stock to be acquired from ARS Pharmaceuticals via a stock option exercise paid in cash on 08/19/2026, then potentially resold in compliance with Rule 144 resale conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR